Chief investigator Professor Alan Burnett, from Cardiff Universitys School of Medicine, commented on the findings:
These promising results demonstrate how targeting a protein present in more than 90 per cent of AML patients can boost treatment without excessively increasing side effects.
Although there has been some controversy around the use of GO following its withdrawal in the US two years ago, these results appear extremely promising and suggest no such cause for concern if the appropriate dose is given. Crucially, this represents some of the first progress in treating AML patients of this age group for at least 20 years.
More top news
Events company Secret Cinema is planning to screen a film in protest at what they have called the 'censorship' of The Interview.
Sepp Blatter's £19 million attempt to immortalise Fifa on screen could do with a sequel. How about The Untouchables or The Usual Suspects?
Some of the children at the Royal Free Hospital in London were less than impressed with their visit from Alex Oxlade-Chamberlain.